

\$%ASTN;HighlightOn= ***;HighlightOff=*** ;

Connecting via winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1635KXH

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 May 10 PROUSDDR now available on STN
NEWS 4 May 19 PROUSDDR: One FREE connect hour, per account, in both May
and June 2004
NEWS 5 May 12 EXTEND option available in structure searching
NEWS 6 May 12 Polymer links for the POLYLINK command completed in REGISTRY
NEWS 7 May 17 FRFULL now available on STN
NEWS 8 May 27 New UPM (Update Code Maximum) field for more efficient patent
SDIs in Caplus
NEWS 9 May 27 Caplus super roles and document types searchable in REGISTRY
NEWS 10 May 27 Explore APOLLIT with free connect time in June 2004
NEWS 11 Jun 22 STN Patent Forums to be held July 19-22, 2004
NEWS 12 Jun 28 Additional enzyme-catalyzed reactions added to CASREACT
NEWS 13 Jun 28 ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG,
and WATER from CSA now available on STN(R)

NEWS EXPRESS MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS world wide web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

*MARPATPREV - Preview File for the CAS Patent Markush File

* The files listed above are temporarily unavailable.

FILE 'HOME' ENTERED AT 10:24:53 ON 06 JUL 2004

=> b medline caplus lifesci embase uspatfull biosis

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

0.63

0.63

FILE 'MEDLINE' ENTERED AT 10:26:31 ON 06 JUL 2004

FILE 'CAPLUS' ENTERED AT 10:26:31 ON 06 JUL 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'LIFESCI' ENTERED AT 10:26:31 ON 06 JUL 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'USPATFULL' ENTERED AT 10:26:31 ON 06 JUL 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 10:26:31 ON 06 JUL 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

=> s atcc(2n)39149
L1 16 ATCC(2N) 39149

=> dup rem l1
PROCESSING COMPLETED FOR L1
L2 12 DUP REM L1 (4 DUPLICATES REMOVED)

=> d 12 ibib abs tot

L2 ANSWER 12 OF 12 USPATFULL on STN
ACCESSION NUMBER: 86:38190 USPATFULL
TITLE: Antibiotic 13-384 complex from Micromonospora
carbonacea var africana
INVENTOR(S): Waitz, Jay A., Warren, NJ, United States
Patel, Mahesh G., Verona, NJ, United States
Marquez, Joseph A., Montclair, NJ, United States
Kalyanpur, Manohar G., Winchester, MA, United States
Horan, Ann C., Summit, NJ, United States
PATENT ASSIGNEE(S): Schering Corporation, Kenilworth, NJ, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4597968		19860701
APPLICATION INFO.:	US 1984-623266		19840621 (6)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1982-405822, filed on 6 Aug 1982, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Goldberg, Jerome D.		
LEGAL REPRESENTATIVE:	Hoffman, Thomas D., Rosen, Gerald S.		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	10 Drawing Figure(s); 10 Drawing Page(s)		
LINE COUNT:	753		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	The antibiotic 13-384 complex is elaborated by a new variety of Micromonospora carbonacea; namely Micromonospora carbonacea var africana NRRL 15099.		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 1 OF 12 USPATFULL on STN
ACCESSION NUMBER: 2004:133296 USPATFULL
TITLE: Everninomicin biosynthetic genes
INVENTOR(S): Hosted, Thomas J., Summit, NJ, UNITED STATES
Wang, Tim X., Roselle Park, NJ, UNITED STATES
Horan, Ann C., Summit, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004101832	A1	20040527
APPLICATION INFO.:	US 2001-758759	A1	20010111 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-175751P	20000112 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530	
NUMBER OF CLAIMS:	34	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	55 Drawing Page(s)	
LINE COUNT:	2396	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	This invention is directed to nucleic acids which encode the proteins	

of the nucleic acids and proteins to produce compounds exhibiting antibiotic activity based on the everninomycin structure. The DNA sequence for the gene clusters responsible for encoding everninomycin biosynthetic genes, which provide the machinery for producing everninomycin, are provided. Thus, this invention provides the nucleic acid sequences needed to synthesize novel everninomycin-related compounds based on everninomycin, arising from modifications of the DNA sequence designed to change glycosyl and modified orsellinic acid groups contained in everninomycin. A Micromonospora site-specific integrase gene is also provided, which can be incorporated in a vector for integration into any actinomycete, and, particularly into Monospora. Thus, the invention further provides methods for introducing heterologous genes into an actinomycete chromosome using this particular vector.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 2 OF 12 USPATFULL on STN

ACCESSION NUMBER: 2003:318620 USPATFULL
 TITLE: Compositions and methods for identifying and distinguishing orthosomycin biosynthetic loci
 INVENTOR(S): Farnet, Chris M., Outremont, CANADA
 Zazopoulos, Emmanuel, Montreal, CANADA
 Staffa, Alfredo, Saint-Laurent, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003224364	A1	20031204
APPLICATION INFO.:	US 2002-107431	A1	20020328 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-769734, filed on 26 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-279095P	20010328 (60)
	US 2001-279709P	20010330 (60)
	US 2001-285214P	20010420 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	George A. Loud, LORUSSO & LOUD, 3137 Mount Vernon Avenue, Alexandria, VA, 22305	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	13 Drawing Page(s)	
LINE COUNT:	5494	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compositions and methods useful to identify orthosomycin biosynthetic gene clusters. The invention also provides compositions and methods useful to distinguish everninomycin-type orthosomycin gene clusters and avilamycin-type orthosomycin gene clusters. An orthosomycin gene cluster may be identified using compositions of the invention such as hybridization probes, PCR primers derived from specific protein families responsible for the unique structural features that distinguish orthosomycins, everninomycin-type orthosomycins and avilamycin-type orthosomycins. An orthosomycin gene cluster may be identified using compositions of the invention such as the sequence code for the reference sequences stored on computer readable medium.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 3 OF 12 MEDLINE on STN

DUPLICATE 1

ACCESSION NUMBER: 2003410675 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 12949170
 TITLE: Development of the Micromonospora carbonacea var. africana ***ATCC*** ***39149*** bacteriophage pMLP1 integrase for site-specific integration in Micromonospora spp.
 AUTHOR: Alexander Dylan C; Devlin David J; Hewitt Duane D; Horan Ann C; Hosted Thomas J
 CORPORATE SOURCE: New Lead Discovery, Schering Plough Research Institute, 2015 Galloping Hill Road, K15-B425-MS4800, Kenilworth, NJ 07033, USA.
 SOURCE: Microbiology (Reading, England), (2003 Sep) 149 (Pt 9) 2443-53.
 Journal code: 9430468. ISSN: 1350-0872.
 PUB. COUNTRY: England: United Kingdom

LANGUAGE: English
FILE SEGMENT: Priority Journals
OTHER SOURCE: GENBANK-AY150027; GENBANK-AY150028; GENBANK-AY150029;
GENBANK-AY150030; GENBANK-AY150031; GENBANK-AY150032;
GENBANK-AY150033
ENTRY MONTH: 200403
ENTRY DATE: Entered STN: 20030903
Last Updated on STN: 20040305
Entered Medline: 20040304

AB Micromonospora carbonacea var. africana ***ATCC*** ***39149***
contains a temperate bacteriophage, pMLP1, that is present both as a
replicative element and integrated into the chromosome. Sequence analysis
of a 4.4 kb KpnI fragment revealed pMLP1 att/int functions consisting of
an integrase, an excisionase and the phage attachment site (attP).
Plasmids pSPRH840 and pSPRH910, containing the pMLP1 att/int region, were
introduced into Micromonospora spp. by conjugation from Escherichia coli.
Sequence analysis of DNA flanking the integration site confirmed
site-specific integration into a tRNA^{His} gene in the chromosome. The
pMLP1 attP element and chromosomal bacterial attachment (attB) site
contain a 24 bp region of sequence identity located at the 3' end of the
tRNA. Integration of pMLP1-based plasmids in M. carbonacea var. africana
caused a loss of the pMLP1 phage. Placement of an additional attB site
into the chromosome allowed integration of pSPRH840 into the alternate
attB site. Plasmids containing the site-specific att/int functions of
pMLP1 can be used to integrate genes into the chromosome.

L2 ANSWER 4 OF 12 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 2002:98239 BIOSIS
DOCUMENT NUMBER: PREV200200098239
TITLE: Characterization of the biosynthetic gene cluster for the
oligosaccharide antibiotic, evernimicin, in Micromonospora
carbonacea var. africana ATCC39149.
AUTHOR(S): Hosted, T. J. [Reprint author]; Wang, T. X.; Alexander, D.
C.; Horan, A. C.
CORPORATE SOURCE: Schering-Plough Research Institute, 2015 Galloping Hill
Road, Kenilworth, NJ, 07033, USA
SOURCE: Journal of Industrial Microbiology and Biotechnology,
(December, 2001) vol. 27, No. 6, pp. 386-392. print.
ISSN: 1367-5435.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 24 Jan 2002
Last Updated on STN: 25 Feb 2002

AB Evernimicin (EV) belongs to the orthosomycin class of antibiotics and
consists of several modified L- and D-deoxysugars containing unusual
orthoester and glycosyl linkages and two orsellinic acid groups, one that
is halogenated. The EV biosynthetic gene cluster from Micromonospora
carbonacea var. africana ATCC39149 was localized by hybridization to a
dTDP-D-glucose 4,6-dehydratase probe and a 120-kb region containing the EV
biosynthetic cluster and surrounding regions has been sequenced. BLAST
analysis has identified a type I polyketide synthase for orsellinic acid
biosynthesis as well as enzymes required for L- and D-deoxyglucose and
D-deoxymannose synthesis. In addition, genes involved in glycosyltransfer
and resistance were identified. Insertional mutations in several
biosynthetic genes blocked EV production, indicating a role for these
genes in EV biosynthesis.

L2 ANSWER 5 OF 12 USPATFULL on STN
ACCESSION NUMBER: 1998:98898 USPATFULL
TITLE: Water soluble antibiotics
INVENTOR(S): Girijavallabhan, Viyyoor M., Parsippany, NJ, United
States
Saksena, Anil K., Upper Montclair, NJ, United States
Bennett, Frank, Piscataway, NJ, United States
Jao, Edwin, Warren, NJ, United States
Patel, Naginbhai M., Piscataway, NJ, United States
Ganguly, Ashit, Upper Montclair, NJ, United States
PATENT ASSIGNEE(S): Schering Corporation, Kenilworth, NJ, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5795874		19980818
APPLICATION INFO.:	US 1996-770469		19961220 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-577656, filed on 22 Dec 1995, now patented, Pat. No. US 5652226		

FILE SEGMENT: Granted
PRIMARY EXAMINER: Ivy, C. Warren
ASSISTANT EXAMINER: Aulakh, Charanjit S.
LEGAL REPRESENTATIVE: Majka, Joseph T., Hoffman, Thomas D.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 403

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The compound of the formula I ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, and R.sup.8 are as defined herein, are described. These compounds are antibacterial agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 6 OF 12 USPATFULL on STN

ACCESSION NUMBER: 1998:79153 USPATFULL
TITLE: Lipophilic oligosaccharide antibiotic compositions
INVENTOR(S): Patel, Mahesh G., Verona, NJ, United States
Gullo, Vincent P., Liberty Corner, NJ, United States
Hare, Roberta S., Gillette, NJ, United States
Loebenberg, David, Monsey, NY, United States
Kwon, Heewon Y., Warren, NJ, United States
Miller, George H., Montville, NJ, United States
PATENT ASSIGNEE(S): Schering Corporation, Kenilworth, NJ, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5776912		19980707
APPLICATION INFO.:	US 1996-770470		19961220 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Peselev, Elli		
LEGAL REPRESENTATIVE:	Hoffman, Thomas D.		
NUMBER OF CLAIMS:	27		
EXEMPLARY CLAIM:	20,27		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	1179		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An aqueous pharmaceutical composition comprising a lipophilic oligosaccharide antibiotic salt, e.g., the N-methylglucamine salt of the everninomicin-type antibiotic of Formula III together with a binding agent such as human serum albumin or recombinant human albumin and a tonicity agent such as mannitol, is disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 7 OF 12 USPATFULL on STN

ACCESSION NUMBER: 97:66113 USPATFULL
TITLE: Water soluble antibiotics
INVENTOR(S): Girijavallabhan, Viyyoor M., Parsippany, NJ, United States
Saksena, Anil K., Upper Montclair, NJ, United States
Bennett, Frank, Piscataway, NJ, United States
Jao, Edwin, Warren, NJ, United States
Patel, Naginbhai M., Piscataway, NJ, United States
Ganguly, Ashit, Upper Montclair, NJ, United States
PATENT ASSIGNEE(S): Schering Corporation, Kenilworth, NJ, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5652226		19970729
APPLICATION INFO.:	US 1995-577656		19951222 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Richter, Johann		
ASSISTANT EXAMINER:	Stockton, Laura L.		
LEGAL REPRESENTATIVE:	Boxer, Matthew, Hoffman, Thomas D., Majka, Joseph T.		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1		
LINE COUNT:	424		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The compound of the formula I ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, and R.sup.8 are as defined herein, are described. These compounds are antibacterial agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 8 OF 12 USPATFULL on STN

ACCESSION NUMBER: 97:36174 USPATFULL
TITLE: Lipophilic oligosaccharide antibiotic salt compositions
INVENTOR(S): Patel, Mahesh, Verona, NJ, United States
Gullo, Vincent P., Liberty Corner, NJ, United States
Hare, Roberta, Gilette, NJ, United States
Loebenberg, David, Monsey, NY, United States
Morton, James B., Belleville, NJ, United States
Miller, George H., Montville, NJ, United States
Kwon, Heewon Y., Edison, NJ, United States
PATENT ASSIGNEE(S): Schering Corporation, Kenilworth, NJ, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5624914		19970429
APPLICATION INFO.:	US 1994-211700		19940412 (8)
	WO 1992-US8565		19921014
			19940412 PCT 371 date
			19940412 PCT 102(e) date
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kight, John		
ASSISTANT EXAMINER:	White, Everett		
LEGAL REPRESENTATIVE:	Hoffman, Thomas D.		
NUMBER OF CLAIMS:	22		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	1351		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutically acceptable compositions of matter comprising a lipophilic oligosaccharide antibiotic, e.g., the everninomicin-type antibiotic of Formula III, at least a stoichiometric amount of a base, e.g., N-methylglucamine, an amount of, e.g., hydroxypropyl-.beta.-cyclodextrin, and optionally a pharmaceutically acceptable non-ionic surfactant, e.g., Tween-80, pharmaceutical compositions containing such compositions of matter, methods of treating and preventing susceptible bacterial infections in animals especially human beings as well as a method of preventing adverse reaction syndrome while simultaneously delivering an antiinfective amount of a lipophilic oligosaccharide antibiotic such as that of Formula III to said animals as well as the use of the compositions of matter for the preparation of a medicament for such treating or preventing are disclosed. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 9 OF 12 USPATFULL on STN

ACCESSION NUMBER: 88:55542 USPATFULL
TITLE: Substituted oligosaccharide antibodies
INVENTOR(S): Ganguly, Ashit K., Upper Montclair, NJ, United States
Sarre, Olga, Verona, NJ, United States
Girijavallabhan, Viyyoor M., Parsippany, NJ, United States
PATENT ASSIGNEE(S): Schering Corporation, Kenilworth, NJ, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4767748		19880830
APPLICATION INFO.:	US 1986-900873		19860827 (6)
DISCLAIMER DATE:	20031111		
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1985-787405, filed on 15 Oct 1985, now patented, Pat. No. US 4622314		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Griffin, Ronald W.		
ASSISTANT EXAMINER:	Carson, Nancy S.		
LEGAL REPRESENTATIVE:	Hoffman, Thomas D., Rosen, Gerald S.		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	7		
LINE COUNT:	482		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound represented by formula I ##STR1## wherein R is hydrogen, or ##STR2## wherein R.sup.1 is N-acylamino, N-alkylamino, N,N-dialkylamino,

thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 10 OF 12 USPATFULL on STN

ACCESSION NUMBER: 88:21096 USPATFULL
TITLE: Micromonospora carbonacea var africana
INVENTOR(S): Waitz, Jay A., Portola Valley, CA, United States
Horan, Ann C., Summit, NJ, United States
PATENT ASSIGNEE(S): Schering Corporation, Kenilworth, NJ, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4735903		19880405
APPLICATION INFO.:	US 1986-845094		19860327 (6)
RELATED APPLN. INFO.:	Division of Ser. No. US 1984-623266, filed on 21 Jun 1984, now patented, Pat. No. US 4597968 which is a continuation-in-part of Ser. No. US 1982-405822, filed on 6 Aug 1982, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Weimar, Elizabeth		
LEGAL REPRESENTATIVE:	Hoffman, Thomas D., Rosen, Gerald S.		
NUMBER OF CLAIMS:	1		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	10 Drawing Figure(s); 10 Drawing Page(s)		
LINE COUNT:	695		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A new variety of Micromonospora carbonacea, namely Micromonospora carbonacea var africana NRRL 15099, ***ATCC*** ***39149*** .

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 11 OF 12 USPATFULL on STN

ACCESSION NUMBER: 86:63474 USPATFULL
TITLE: Substituted oligosaccharide antibiotics
INVENTOR(S): Ganguly, Ashit K., Upper Montclair, NJ, United States
Sarre, Olga, Verona, NJ, United States
Girijavallabhan, Viyyoor M., Parsippany, NJ, United States
PATENT ASSIGNEE(S): Schering Corporation, Kenilworth, NJ, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4622314		19861111
APPLICATION INFO.:	US 1985-787405		19851015 (6)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Brown, Johnnie R.		
LEGAL REPRESENTATIVE:	Hoffman, Thomas D., Rosen, Gerald S., Miller, Stephen I.		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	9		
LINE COUNT:	292		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is disclosed desevernitroze, acetamido, ethylamino and diethylamino derivatives of antibiotic 13-384 components 1 and 5 represented by the following formula ##STR1## wherein R is hydrogen, or ##STR2## wherein R.sup.1 is acetamide, ethylamine, diethylamine, N-hydroxylamino, nitroso or the pharmaceutically acceptable salts thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 12 OF 12 USPATFULL on STN

ACCESSION NUMBER: 86:38190 USPATFULL
TITLE: Antibiotic 13-384 complex from Micromonospora carbonacea var africana
INVENTOR(S): Waitz, Jay A., Warren, NJ, United States
Patel, Mahesh G., Verona, NJ, United States
Marquez, Joseph A., Montclair, NJ, United States
Kalyanpur, Manohar G., Winchester, MA, United States
Horan, Ann C., Summit, NJ, United States
PATENT ASSIGNEE(S): Schering Corporation, Kenilworth, NJ, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4597968		19860701
APPLICATION INFO.:	US 1984-623266		19840621 (6)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1982-405822, filed on 6 Aug 1982, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Goldberg, Jerome D.		
LEGAL REPRESENTATIVE:	Hoffman, Thomas D., Rosen, Gerald S.		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	10 Drawing Figure(s); 10 Drawing Page(s)		
LINE COUNT:	753		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The antibiotic 13-384 complex is elaborated by a new variety of *Micromonospora carbonacea*; namely *Micromonospora carbonacea* var *africana* NRRL 15099.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d kwic tot

L2 ANSWER 1 OF 12 USPATFULL on STN

SUMM [0002] Everninomicin is an oligosaccharide antibiotic belonging to the orthosomycin group of antibiotics produced by *Micromonospora carbonacea* var. *africana* (***ATCC*** ***39149*** , SCC 1413) and is useful as a human medicine. Everninomicin chemically consists of several glycosyl residues attached to modified orsellinic. . .

DETD [0146] The DNA sequence of the *Micromonospora carbonacea* var. *africana* (***ATCC*** ***39149***) everninomicin biosynthetic region was obtained by sequencing inserts of recombinant DNA subclones containing contiguous or overlapping DNA segments of the. . .

L2 ANSWER 2 OF 12 USPATFULL on STN

DETD . . . var. *aurantiaca* NRRL 2997 is sometimes referred to as EVER, the biosynthetic locus for everninomicin from *Micromonospora carbonacea* var. *africana* (***ATCC*** ***39149*** , SCC 1413) is sometimes referred to as EVEA, the biosynthetic locus for an avilamycin-like compound from *Streptomyces mobarensis* is sometimes. . .

L2 ANSWER 3 OF 12 MEDLINE on STN DUPLICATE 1

TI Development of the *Micromonospora carbonacea* var. *africana* ***ATCC*** ***39149*** bacteriophage pMLP1 integrase for site-specific integration in *Micromonospora* spp.

AB *Micromonospora carbonacea* var. *africana* ***ATCC*** ***39149*** contains a temperate bacteriophage, pMLP1, that is present both as a replicative element and integrated into the chromosome. Sequence analysis. . .

L2 ANSWER 4 OF 12 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN

ORGN Classifier
 Actinoplanetes 08830
 Super Taxa
 Actinomycetes and Related Organisms; Eubacteria; Bacteria;
 Microorganisms
 Organism Name
Micromonospora carbonacea var. *africana*: ***ATCC*** ***39149***
 Taxa Notes
 Bacteria, Eubacteria, Microorganisms

L2 ANSWER 5 OF 12 USPATFULL on STN

SUMM . . . of formula I' (compound 10 of Scheme I) may be obtained by fermentation of *Micromonospora carbonacea* var. *africana* NRRL 15099 ***ATCC*** ***39149*** or, more preferably, by an improved strain thereof, obtained as described in WO 93/07904 published Apr. 29, 1993.

L2 ANSWER 6 OF 12 USPATFULL on STN

DRWD FIG. 1 graphically illustrates the progression, with time, of a typical fermentation of *Micromonospora carbonacea* var. *africana*, NRRL 15099, ***ATCC*** ***39149*** .

DETD . . . ##STR10## are isolated from an antibiotic 13-384 complex produced by fermentation of the organism *Micromonospora carbonacea* var. *africana*, NRRL 15099, ***ATCC*** ***39149*** . Antibiotic

DETD R.sub.4 and R.sub.5 are each defined as hereinabove in reference. . .
The preferred compound of the Formula III may be obtained by
fermentation of *Micromonospora carbonacea* var. *africana* NRRL 15099,
ATCC ***39149*** or, more preferably, by an improved strain
thereof, obtained as hereinafter described.
DETD Utilizing the strain SCC 1413 of the culture NRRL 15099, ***ATCC***
39149, the preferred compound of the Formula III may suitably be
obtained by the procedures outlined in Example I of U.S. . . .
DETD We have developed an improved strain from SCC1413, NRRL 15099,
ATCC ***39149*** using standard mutagenesis agents and
obtained strains producing improved yields of the preferred
evernimicin-type antibiotic compound of the Formula III. In a specific
example, the parent strain SCC 1413, NRRL 15099, ***ATCC***
39149 was exposed to an amount of the mutagenesis agent,
N-nitrosoguanidine (NTG) sufficient to kill 90% of a culture of SCC
1413, ***ATCC*** ***39149***, NRRL 15099. Fifteen hundred
surviving isolates were examined for enhanced biological activity
against *S. aureus* and *E. coli* to determine. . .
DETD TABLE 6

Flask Comparison of SCC's 1413, 1631, 1756 and 2146
Strains of *Micromonospora Carbonacea*
var *africana* NRRL 15099, ***ATCC*** ***39149***
Titer of the compound of Formula III and
Nitroso Analog (1A) Thereof (.mu.g/ml)
Culture 1 (NO.sub.2)
1a (NO) combined (1 + 1a)

SCC 1413 5.
DETD A 100 liter fermentation of strain SCC 2146 of *Micromonospora carbonacea*
var. *africana* NRRL 15099, ***ATCC*** ***39149*** improved as
described hereinabove, was conducted in accordance with the procedures
of Example 1 B of U.S. Pat. No. 4,597,968. . .

L2 ANSWER 7 OF 12 USPATFULL on STN
DETD . . . of formula I' (compound 10 of Scheme I) may be obtained by
fermentation of *Micromonospora carbonacea* var. *africana* NRRL 15099
ATCC ***39149*** or, more preferably, by an improved strain
thereof, obtained as described in WO 93/07904 published Apr. 29, 1993.

L2 ANSWER 8 OF 12 USPATFULL on STN
DRWD FIG. 1 graphically illustrates the progression, with time, of a typical
fermentation of *Micromonospora carbonacea* var. *africana*, NRRL 15099,
ATCC ***39149***.
DETD . . . ##STR11## are isolated from an antibiotic 13-384 complex
produced by fermentation of the organism *Micromonospora carbonacea* var.
africana, NRRL 15099, ***ATCC*** ***39149***. Antibiotic
components 1 (Formula II, X=NO.sub.2 and Y, R.sub.2, R.sub.3, R.sub.4
and R.sub.5 are each defined as hereinabove in reference. . .
DETD The preferred compound of the Formula III may be obtained by
fermentation of *Micromonospora carbonacea* var. *africana* NRRL 15099,
ATCC ***39149*** or, more preferably, by an improved strain
thereof, obtained as hereinafter described.
DETD Utilizing the strain SCC 1413 of the culture NRRL 15099, ***ATCC***
39149, the preferred compound of the Formula III may suitably be
obtained by the procedures outlined in Example 1 of U.S. . . .
DETD We have developed an improved strain from SCC1413, NRRL 15099,
ATCC ***39149*** using standard mutagenesis agents and
obtained strains producing improved yields of the preferred
evernimicin-type antibiotic compound of the Formula III. In a specific
example, the parent strain SCC 1413, NRRL 15099, ***ATCC***
39149 was exposed to an amount of the mutagenesis agent,
N-nitrosoguanidine (NTG) sufficient to kill 90% of a culture of SCC
1413, ***ATCC*** ***39149***, NRRL 15099. Fifteen hundred
surviving isolates were examined for-enhanced biological activity
against *S. aureus* and *E. coli* to determine which. . .
DETD TABLE 6

Flask Comparison of SCC's 1413, 1631, 1756 and 2146
Strains of *Micromonospora Carbonacea* var *africana* NRRL
15099, ***ATCC*** ***39149***
Titer of the compound of Formula III and Nitroso Analog (1A)
Thereof (.mu.g/ml)
Culture 1 (NO.sub.2)
1a (NO) combined (1 + 1a)

DETD A 100 liter fermentation of strain SCC 2146 of *Micromonospora carbonacea* var. *africana* NRRL 15099, ***ATCC*** ***39149*** improved as described hereinabove, was conducted in accordance with the procedures of Example 1B of U.S. Pat. No. 4,597,968 except. . .

L2 ANSWER 9 OF 12 USPATFULL on STN
SUMM . . . invention relates to anti-bacterially active derivatives of an antibiotic complex produced by *Micromonospora carbonacea* var *africana* var nov. NRRL 15099, ***ATCC*** ***39149***, which is designated antibiotic 13-384 in commonly assigned U.S. Pat. No. 4,597,968 which is incorporated herein by reference. This complex,. . .

L2 ANSWER 10 OF 12 USPATFULL on STN
AB A new variety of *Micromonospora carbonacea*, namely *Micromonospora carbonacea* var *africana* NRRL 15099, ***ATCC*** ***39149***
SUMM . . . under controlled conditions using a biologically pure culture of the new microorganism, *Micromonospora carbonacea* var *africana* var nov. NRRL 15099, ***ATCC*** ***39149***
DETD . . . of the collection of the American Type Culture Collection (ATCC) in Rockville, Md. where it has been assigned accession number ***ATCC*** ***39149***. Subcultures of *Micromonospora carbonacea* var *africana* ***ATCC*** ***39149*** are available to the public without restriction. Use of the microorganism is dependent on U.S. Patent Laws.
DETD . . . variety of the species *Micromonospora carbonacea*. It is proposed that the culture be designated *Micromonospora carbonacea* var *africana* NRRL 15099, ***ATCC*** ***39149***. This strain is under stood to be the type strain of the new variety.
DETD Culture characteristics of the microorganism, *Micromonospora carbonacea* var *africana* NRRL 15099, ***ATCC*** ***39149*** on various standard media are reported in Table 5.
DETD Growth of the microorganism, NRRL 15099/ ***ATCC*** ***39149*** on various carbon compounds is reported in Table 6.
DETD Physiologic characteristics of microorganism, NRRL 15099/ ***ATCC*** ***39149*** are reported in Table 7.
DETD Whole cell analysis of the culture of the microorganism NRRL 15099/ ***ATCC*** ***39149*** found mesodiaminopimelic acid, xylose and arabinose.

L2 ANSWER 11 OF 12 USPATFULL on STN
SUMM . . . invention relates to antibacterially active derivatives of an antibiotic complex produced by *Micromonospora carbonacea* var *africana* var nov. NRRL 15099, ***ATCC*** ***39149***, which is designated antibiotic 13-384 in commonly assigned U.S. patent application Ser. No. 623,266, filed June 21, 1984, which application. . .

L2 ANSWER 12 OF 12 USPATFULL on STN
SUMM . . . under controlled conditions using a biologically pure culture of the new microorganism, *Micromonospora carbonacea* var *africana* var. nov. NRRL 15099, ***ATCC*** ***39149***
DETD . . . of the collection of the American Type Culture Collection (ATCC) in Rockville, Md. where it has been assigned accession number ***ATCC*** ***39149***. Subcultures of *Micromonospora carbonacea* var *africana* ***ATCC*** ***39149*** are available to the public without restriction. Use of the microorganism is dependent on U.S. Patent Laws.
DETD . . . variety of the species *Micromonospora carbonacea*. It is proposed that the culture be designated *Micromonospora carbonacea* var *africana* NRRL 15099, ***ATCC*** ***39149***. This strain is under stood to be the type strain of the new variety.
DETD Culture characteristics of the microorganism, *Micromonospora carbonacea* var *africana* NRRL 15099, ***ATCC*** ***39149*** on various standard media are reported in Table 5.
DETD Growth of the microorganism, NRRL 15099/ ***ATCC*** ***39149*** on various carbon compounds is reported in Table 6.
DETD Physiologic characteristics of microorganism, NRRL 15099/ ***ATCC*** ***39149*** are reported in Table 7.
DETD Whole cell analysis of the culture of the microorganism NRRL 15099/ ***ATCC*** ***39149*** found mesodiaminopimelic acid, xylose and arabinose.

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	38.91	39.54

STN INTERNATIONAL LOGOFF AT 10:34:11 ON 06 JUL 2004

L Number	Hits	Search Text	DB	Time stamp
25	3	(everninomicin adj3 biosynthesis) and gene	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/06 11:30
-	3	(t and hosted).in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/01 10:34
-	5451	(t and wang).in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/01 10:30
-	112	(a and horan).in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/01 10:29
-	32	(ann and horan).in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/01 10:32
-	25	(tim and wang).in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/01 10:30
-	0	((t and hosted).in.) and ((ann and horan).in.) and ((tim and wang).in.)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/01 10:32
-	4	(thomas and hosted).in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/01 10:34
-	1	((ann and horan).in.) and ((tim and wang).in.) and ((thomas and hosted).in.)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/01 10:34
-	11	everninomicin and biosynthesis	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/01 10:35
-	7	everninomicin and biosynthesis and gene and (path or pathway)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/01 10:36
-	0	(everninomicin and biosynthesis and gene and (path or pathway)) not ((everninomicin and biosynthesis) or (everninomicin and biosynthesis and gene))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/01 10:36
-	11	everninomicin and biosynthesis and gene	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/01 10:43
-	3	(everninomicin adj3 biosynthesis)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/01 10:50
-	1172	micromonospora	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/01 10:50

-	50	micromonospora adj2 carbonacea	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/01 10:51
-	30	everninomicin and (micromonospora adj2 carbonacea)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/01 11:06
-	1152	actinomycete	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/01 11:07
-	9	actinomycete and everninomicin	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/01 11:07
-	72	everninomicin	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/01 12:09